Thus, our strategy of targeting HCC cells that produce AFP-L3 looks promising, since it could overcome chemoresistance via an effective delivery system for chemotherapeutic agents and molecular targeting drugs (Fig 7). This evidence concerns the gene AFP and hepatocellular carcinoma.